Fangyuan Pharmaceutical has set up an institute (the Jiangsu Institute of Microbiology), two R&D workstations (the Nanjing University Chen Hongyuan Academic Workstation and the China Pharmaceutical University Wang Guangji Academic Workstation) and three R&D centers (the Jiangsu Semi-Synthetic Antibiotics Engineering Research Center, the Jiangsu Microbial Pharmaceutics Engineering Research Center and the Jiangsu Enterprise Technology Center), and brought in foreign specialists who will work with the firm and the various R&D units to jointly develop innovative drugs in one of the world's most advanced scientific fields.
The etimicin sulfate HPLC-PAD test method jointly developed by Fangyuan Pharmaceutical and partnering organizations was announced in Chinese Pharmacopoeia 2015 and copied by pharmacopoeias in Europe and the United States. The company is developing two Class 1 (according to the Chinese FDA classification system) new drugs for the treatment of leukemia and colon cancer, as well as four Class 3 generic drugs.
Changzhou National Hi-Tech District's Life and Health Industrial Park is home to Changzhou Qianhong Biopharma, Zilong Pharmaceutical, Genovate Biotechnology, Intersurgical, Changzhou Cross-straits Life Science Industrial Park, and Chinese Academy of Sciences Genetic Resources (Southern China) R&D Center, with an aggregate investment exceeding 20 billion yuan (approx. US$3 billion). The park has evolved into an environmentally-friendly industrial zone that mainly produces pharmaceutical preparations and medical devices.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fangyuan-pharmaceutical-invests-heavily-in-rd-of-new-drugs-for-treatment-of-superbacteria-300297088.html
SOURCE The Public Promotion Department of Changzhou Xinbei District Commission of CCP